These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31385178)

  • 1. Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization.
    Zeng Z; Fu X; Zhang X; Fu N
    Int Urol Nephrol; 2019 Nov; 51(11):1999-2004. PubMed ID: 31385178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.
    Zhang X; Yang S; Zhang P; Fu N
    Coron Artery Dis; 2020 May; 31(3):284-288. PubMed ID: 31658134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
    Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
    Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
    Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
    Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
    Zhan B; Huang X; Jiang L; Bao H; Cheng X
    Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
    Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
    Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization.
    Watanabe M; Saito Y; Aonuma K; Hirayama A; Tamaki N; Tsutsui H; Murohara T; Ogawa H; Akasaka T; Yoshimura M; Sato A; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K;
    J Cardiol; 2016 Nov; 68(5):412-418. PubMed ID: 26708123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
    Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
    Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial.
    Marashizadeh A; Sanati HR; Sadeghipour P; Peighambari MM; Moosavi J; Shafe O; Firouzi A; Zahedmehr A; Maadani M; Shakerian F; Kiani R; Mohebbi B; Alemzadeh-Ansari MJ; Tahvili R; Naghavi B
    Int Urol Nephrol; 2019 Oct; 51(10):1815-1822. PubMed ID: 31332700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
    Fan Z; Li Y; Ji H; Jian X
    Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of brain natriuretic peptide
    Mei Z; Luo S; Chen P; Zhang Q; Zhou L; Zhu C; Zhu H; Jin L
    PeerJ; 2022; 10():e12975. PubMed ID: 35228908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
    Fu N; Liang M; Yang S
    Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures.
    Feldkamp T; Luedemann M; Spehlmann ME; Freitag-Wolf S; Gaensbacher J; Schulte K; Bajrovic A; Hinzmann D; Hippe HJ; Kunzendorf U; Frey N; Luedde M
    Clin Res Cardiol; 2018 Feb; 107(2):148-157. PubMed ID: 28939956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.